• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA approves expanded indication for Supernus’ Qelbree for ADHD

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 02, 2022 at 11:12: AM
via The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.

article source
 




Top Bottom
Back
Quote